Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot bleeding risk in Moms-to-Be faster

NCT ID NCT06255496

Diagnosis Sponsor: HemoSonics LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called Quantra QStat that measures how well blood clots, compared to standard lab tests. It involved 296 pregnant women or new mothers at risk of heavy bleeding during delivery. The goal was to see if the new device gives faster and reliable results to help doctors manage bleeding emergencies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

296 people

The number who actually took part.

Started

May 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Parturients 18 years or older who are at risk of experiencing an obstetric hemorrhage around the time of delivery.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is greater than18 years. * Subject is pregnant or at least 24 h postpartum * Conventional coagulation tests and/or viscoelastic testing are ordered for concern of possible coagulopathy based on one or more clinical scenarios including hemorrhage, suspected or confirmed placental abruption, amniotic fluid embolism, or placenta accreta spectrum * Subject or subject's LAR is willing to provide informed consent, either prospectively or by deferred consent. Exclusion Criteria: * Subject is younger than 18 years old. * Subject or subject's LAR is unwilling or unable to provide informed consent, either prospectively or by deferred consent. * Subject is incarcerated at the time of the study. * Subject is currently enrolled in a distinct study that might confound the results of the proposed study * Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood loss massive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood loss massive Post partum hemorrhage

Contacts and locations

Locations

  • Magee Womens Hospital

    Pittsburgh, Pennsylvania, 15213, United States

  • Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • Parkland Health

    Dallas, Texas, 75235, United States

  • University of Oklahoma Medical Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • University of Utah

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.